NCT01711489已完成1 期
A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Composite of pharmacokinetic (PK) variables of plasma mycophenolic acid (MPA) and phenolic glucuronide of MPA (MPAG): AUClast, AUCinf, Cmax
研究概览
简要总结
The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics (PK) of mycophenolate mofetil (MMF) after single dose administration. Safety and tolerability of isavuconazole will be assessed alone and in combination with MMF.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject has a body weight of at least 45 kg and has a body mass index (BMI) of 18 to 32 kg/m2, inclusive.
- •Results for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be ≤ 1.5 mg/dL
- •The female subject agrees to sexual abstinence, or is surgically sterile, postmenopausal (defined as at least 2 years at Screening without menses), or using a medically acceptable double barrier method (e.g. spermicide and diaphragm, or spermicide and condom) to prevent pregnancy and agrees to continue using this method from Screening until 5 weeks after the follow-up visit at the end of the study; and is not lactating or pregnant as documented by negative pregnancy tests at Screening and Day -
- •The male subject agrees to sexual abstinence, is surgically sterile, or is using a medically acceptable method to prevent pregnancy and agrees to continue using this method from Screening until 5 weeks after the follow-up visit at the end of the study
排除标准
- •The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmia or torsade de pointes, structural heart disease, or family history of Long QT syndrome (suggested by sudden death of a close relative at a young age due to possible or probable cardiac causes).
- •The subject has a history of tuberculosis or exposure to anyone known or suspected to have tuberculosis or any illness that might confound the results of the study or pose additional risk in administering study drug to the subject.
- •The subject has a positive result for hepatitis C antibodies, hepatitis B surface antigen, or QuantiFERON®-TB Gold test at Screening or is known to be positive for human immunodeficiency virus (HIV).
- •The subject has a known or suspected allergy to any of the components of the trial products including mycophenolate mofetil (MMF) or the azole class of compounds, or a history of multiple and/or severe allergies to drugs or foods, or a history of severe anaphylactic reactions.
- •The subject is a smoker (any use of tobacco or nicotine containing products) within 6 months prior to Screening.
- •The subject has had treatment with prescription drugs or complementary and alternative medicines within 14 days prior to Day -1, or over-the-counter medications within 1 week prior to Day -1, with the exception of acetaminophen up to 2 g/day.
- •The subject has a recent history (within the last 2 years) of drug or alcohol abuse, as defined by the investigator, or a positive drug and/or alcohol screen
研究组 & 干预措施
isavuconazole and mycophenolate mofetil
Experimental
Single dose of MMF on Day 1, isavuconazole three times daily (TID) on Days 9 and 10, isavuconazole once daily (QD) Days 11-16, a single dose of MMF on Day 13
干预措施: isavuconazole (Drug)
isavuconazole and mycophenolate mofetil
Experimental
Single dose of MMF on Day 1, isavuconazole three times daily (TID) on Days 9 and 10, isavuconazole once daily (QD) Days 11-16, a single dose of MMF on Day 13
干预措施: Mycophenolate mofetil (Drug)
结局指标
主要结局
Composite of pharmacokinetic (PK) variables of plasma mycophenolic acid (MPA) and phenolic glucuronide of MPA (MPAG): AUClast, AUCinf, Cmax
时间窗: Days 1 and 13: predose, and at 0.5, .75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 48, 72, and 96 hours postdose
Area under the concentration-time curve (AUC) from the time of dosing to the last quantifiable concentration (AUClast), AUC from the time of dosing to infinity (AUCinf), and maximum concentration (Cmax)
次要结局
- PK of plasma isavuconazole: Trough concentration (Ctrough)(Day 11, Days 14-16, predose and on Day 17, predose and 24 hours postdose)
- Composite of PK variables of plasma isavuconazole concentration: AUCtau, Cmax, and tmax(Days 12 and 13: predose and at 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, and 24 hours postdose)
- Composite of PK variables of plasma MPA: tmax, t1/2, Vz/F, and CL/F(Days 1 and 13: predose, and at 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 48, 72, and 96 hours postdose)
- Composite of PK variables of plasma MPAG: tmax and t1/2(Days 1 and 13: predose, and at 0.5, .75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 48, 72, and 96 hours postdose)
- Safety assessed through the reporting of adverse events, laboratory evaluations, electrocardiograms (ECGs) and vital signs(Through Day 17)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult SubjectsPharmacokinetics of IsavuconazolePharmacokinetics of DextromethorphanHealthy Adult VolunteersNCT01651325Astellas Pharma Global Development, Inc.24
已完成
1 期
Drug Interaction Study of Isavuconazole and DigoxinPharmacokinetics of IsavuconazolePharmacokinetics of DigoxinHealthy VolunteersNCT01582412Astellas Pharma Global Development, Inc.24
已完成
1 期
Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male SubjectsPharmacokinetics of IsavuconazolePharmacokinetics of S- and R-warfarinPharmacodynamics of WarfarinHealthy VolunteersNCT01657825Astellas Pharma Global Development, Inc.20
已完成
1 期
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult SubjectsHealthy SubjectsPharmacokinetics of IsavuconazolePharmacokinetics of PrednisoloneNCT01711827Astellas Pharma Global Development, Inc.21
已完成
1 期
Drug Interaction Study of Isavuconazole and MethadonePharmacokinetics of IsavuconazolePharmacokinetics of MethadoneHealthy VolunteersNCT01582425Astellas Pharma Global Development, Inc.24